var data={"title":"Tobramycin (oral inhalation): Drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tobramycin (oral inhalation): Drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/788627?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tobramycin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tobramycin (oral inhalation): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=tobramycin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tobramycin (oral inhalation): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031230\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bethkis;</li>\n      <li>Kitabis Pak;</li>\n      <li>Tobi;</li>\n      <li>Tobi Podhaler;</li>\n      <li>Tobramycin Pak [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031231\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>TOBI;</li>\n      <li>TOBI Podhaler</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031235\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Aminoglycoside</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031283\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis: </b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bethkis, Kitabis Pak, Tobi: 300 mg every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tobi Podhaler: 112 mg (4 x 28 mg capsules) every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-cystic fibrosis bronchiectasis</b> (off-label use): <b>Note:</b> Use may be considered in patients who have &ge;3 exacerbations requiring antibiotic therapy per year; generally given in addition to oral or IV antimicrobials. Inhalation for nebulization:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute exacerbation: </i>80 mg twice daily; <b>Note: </b>Dose prepared from preservative-free tobramycin injection solution (Le 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Suppression: </i>160 mg or 300 mg twice daily. <b>Note:</b> 160 mg dose prepared from preservative-free tobramycin injection solution (Pasteur 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031282\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tobramycin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tobramycin (oral inhalation): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Cystic fibrosis: </b> Children &ge;6 years and Adolescents: Inhalation: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Non-cystic fibrosis bronchiectasis (off-label use):</b> Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031285\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031286\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; does not undergo hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031304\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobi Podhaler: 28 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin Pak: 300 mg/5 mL (5 mL [DSC]) [contains sodium chloride, sodium hydroxide, sulfuric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bethkis: 300 mg/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kitabis Pak: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobi: 300 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031233\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031306\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, for oral inhalation [capsule]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TOBI Podhaler: 28 mg/capsule (224s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031289\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bethkis, Kitabis Pak, Tobi: To be inhaled over ~15 minutes using a handheld reusable nebulizer (PARI-LC PLUS) with a PARI Vios air compressor (Bethkis) or a DeVilbiss Pulmo-Aide air compressor (Kitabis Pak, Tobi). If multiple different nebulizer treatments are required, administer bronchodilator first, followed by chest physiotherapy, any other nebulized medications, and then tobramycin last. Do not mix with other nebulizer medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tobi Podhaler: Capsules should be administered by oral inhalation via Podhaler device following manufacturer recommendations for use and handling. Capsules should be removed from the blister packaging immediately prior to use and  should not be swallowed. Patients requiring bronchodilator therapy should administer the bronchodilator 15 to 90 minutes prior to Tobi Podhaler. The sequence of chest physiotherapy and additional inhaled therapies is at the discretion of the healthcare provider; however, Tobi Podhaler should always be administered last. The Canadian labeling recommends that patients requiring bronchodilator therapy should administer the bronchodilator 15 to 90 minutes prior to administering Tobi Podhaler.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031239\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of cystic fibrosis patients with <i>Pseudomonas aeruginosa</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031240\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Non-cystic fibrosis bronchiectasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031224\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tobramycin may be confused with Trobicin, vancomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031251\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Voice disorder (4% to 14%), headache (11% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Respiratory: Cough (powder: 10% to 48%, solution: 31%), rhinitis (solution: 11% to 35%), pulmonary disease (30% to 34%; includes pulmonary or cystic fibrosis exacerbations), reduced forced expiratory volume (solution: 1% to 31%, powder: 4%), discoloration of sputum (21%), productive cough (18% to 20%), rales (solution: 6% to 19%, powder: 7%), dyspnea (12% to 16%), decreased lung function (7% to 16%), oropharyngeal pain (11% to 14%), hemoptysis (12% to 13%), pharyngolaryngeal pain (powder: 11%, solution: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever (12% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest discomfort (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Malaise (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine: Increased serum glucose (powder: 3%, solution: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (8% to 10%), dysgeusia (powder: 4% to 7%, solution: &lt;1%), vomiting (6%), diarrhea (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Increased erythrocyte sedimentation rate (solution: 8%), eosinophilia (solution: 2%), increased serum immunoglobulins (solution: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (&lt;1% to 5%), myalgia (solution: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Hypoacusis (powder: 10%), tinnitus (2% to 3%), deafness (&le;1%; including unilateral deafness, reported as mild to moderate hearing loss or increased hearing loss)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (7% to 9%), nasal congestion (7% to 8%), wheezing (5% to 7%), throat irritation (2% to 5%), bronchospasm (&le;1% to 5%), laryngitis (solution: &le;5%) bronchitis (solution: 3%), epistaxis (2% to 3%), tonsillitis (solution: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Aphonia, decreased appetite, hypersensitivity reaction, increased bronchial secretions, pneumonitis, pruritus, pulmonary congestion, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031248\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031249\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchospasm: Bronchospasm may occur; bronchospasm or wheezing should be treated appropriately if either arise. Safety and efficacy have not been demonstrated in patients with FEV<sub>1</sub> &lt;40% or &gt;80% predicted (Bethkis, TOBI) or FEV<sub>1</sub> &lt;25% or &gt;80% predicted (TOBI Podhaler) or FEV<sub>1</sub> &lt;25% or &gt;75% predicted (Kitabis Pak), in patients colonized with <i>Burkholderia cepacia</i>, or in patients &lt;6 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: Nephrotoxicity was not observed during tobramycin inhalation clinical studies, but has been associated with aminoglycosides. If nephrotoxicity occurs, discontinue therapy until serum concentrations fall below 2 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease; neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis may occur due to aminoglycoside-related curare-like effect on neuromuscular function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Ototoxicity, as measured by complaints of hearing loss or tinnitus, has been reported. Tinnitus may be a sentinel symptom of ototoxicity, and therefore, the onset of this symptom warrants further investigation. Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia, or dizziness. Patients with known or suspected auditory or vestibular dysfunction should be closely monitored (audiometric evaluations and serum tobramycin concentrations). Consider monitoring serum tobramycin concentrations if neurotoxicity is suspected or with concurrent use of parenteral aminoglycosides. If neurotoxicity occurs, discontinue therapy until serum concentrations fall below 2 mcg/mL. Baseline audiogram should be considered for patients at increased risk of auditory dysfunction. Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031258\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031255\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104956&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031244\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031245\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Aminoglycosides may cause fetal harm if administered to a pregnant woman. Tobramycin crosses the placenta when given by injection. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tobramycin inhalation may be used for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa</i> (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031246\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tobramycin is found in breast milk following injection (Festini 2006; Uwaydah 1975); the extent of excretion following inhalation is not known. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer of the inhalation product recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, aminoglycosides are expected to be poorly distributed into breast milk, limiting systemic exposure to a nursing infant. In general, modification of bowel flora may occur with any antibiotic exposure (Chung 2002). Based on low serum concentrations and low absorption, breast-feeding is generally considered compatible in women using tobramycin for the management of cystic fibrosis (Edenborough 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031293\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">The utility of monitoring serum concentrations in patients with renal impairment should be per health care provider discretion; serum concentrations achieved following inhalation are significantly less than those achieved following parenteral therapy in patients with normal renal function. Monitor serum tobramycin concentrations in patients with known or history of auditory dysfunction, renal dysfunction, and/or concomitant use of nephrotoxic drugs. One hour after inhalation, serum concentrations of 1 to 2 mcg/mL have been observed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031269\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Inhalation: Serum concentrations are ~1 to 2 mcg/mL 1 hour following a dose in patients with normal renal function. Routine monitoring of serum concentrations is not required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031267\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031270\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Peak serum concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solution for inhalation: ~1 mcg/mL following a 300 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder for inhalation: ~1 mcg/mL (range: 0.49 to 1.55 mcg/mL) following a 112 mg dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Powder for inhalation:  V<sub>d</sub> (central compartment) for a typical cystic fibrosis patient: 85.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solution for inhalation: 4.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder for inhalation: ~3 hours (after a single 112 mg dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Powder for inhalation: 60 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45031308\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tobi Podhaler Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">28 mg (8): $434.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Bethkis Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/4 mL (4 mL): $121.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Kitabis Pak Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $96.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Tobi Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $157.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Tobramycin Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (5 mL): $128.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650000\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bramitob (AT, BR, CH, CO, CZ, DE, ES, GB, GR, HR, HU, IE, IL, IT, LT, LV, MT, NL, PL, PT, RU, SK);</li>\n      <li>Bridul (AR);</li>\n      <li>Gemebcin (DE);</li>\n      <li>Nebris (CZ);</li>\n      <li>Tobi (AR, AT, AU, BD, BE, BG, BR, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HU, IE, IL, IT, JP, LB, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, PY, QA, RO, RU, SE, SK, SV, TR, TW);</li>\n      <li>Tobi Podhaler (AU, CO, CZ, FR, GB, HR, IL, IS, LT, LU, MT, NO, PT, SA, SI, SK, TR);</li>\n      <li>Tobradosa (EC);</li>\n      <li>Tobramist (IN);</li>\n      <li>Zoteon (CL);</li>\n      <li>Zoteon Podhaler (CL, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bethkis (tobramycin) [prescribing information]. Woodstock, IL: Chiesi USA Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen,&quot; <i>J Clin Pharm Ther</i>, 1991, 16(3):167-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/1869596/pubmed\" target=\"_blank\" id=\"1869596\">1869596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(Suppl 1):S2-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/18024241 /pubmed\" target=\"_blank\" id=\"18024241 \">18024241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Festini F, Ciuti R, Taccetti G, et al, &quot;Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment,&quot; <i>J Matern Fetal Neonatal Med</i>, 2006, 19(6):375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/16801316/pubmed\" target=\"_blank\" id=\"16801316\">16801316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahler DA, Schowengerdt KO, Fricker FJ, et al, &ldquo;Toxic Serum Trough Concentrations After Administration of Nebulized Tobramycin,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(4):543-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/12680485/pubmed\" target=\"_blank\" id=\"12680485\">12680485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabis Pak (tobramycin inhalation solution) [prescribing information]. Woodstock, IL: Catalent Pharma Solutions, LLC; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Ashley ED, Neuhauser MM, et al; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/20500046/pubmed\" target=\"_blank\" id=\"20500046\">20500046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. <i>Thorax</i>. 2010;65(suppl 1):i1-i58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/20627931/pubmed\" target=\"_blank\" id=\"20627931\">20627931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsey BW, Burns J, Smith A, et al, &ldquo;Safety and Efficacy of Tobramycin for Inhalation in Patients With Cystic Fibrosis: The Results of Two Phase III Placebo Controlled Clinical Trials,&rdquo; <i>Pediatr Pulmonol</i>, 1997, (Suppl 14):137-8, S10.3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsey BW, Dorkin HL, Eisenberg JD, et al, &ldquo;Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis,&rdquo; <i>N Engl J Med</i>, 1993, 328(24):1740-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/8497284/pubmed\" target=\"_blank\" id=\"8497284\">8497284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw PK, Braun TL, Liebergen A, et al, &ldquo;Aerosolized Tobramycin Pharmacokinetics in Cystic Fibrosis Patients,&rdquo; <i>J Pediatr Pharm Pract</i>, 1997, 2(1):23-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobi (tobramycin) [prescribing information]. East Hanover, NJ: Novartic Pharmaceuticals; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobi Podhaler (tobramycin) [prescribing information]. East Hanover, NJ: Novartic Pharmaceuticals Corporation; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uwaydah M, Bibi S, and Salman S, &quot;Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation,&quot; <i>J Antimicrob Chemother</i>, 1975, 1(4):429-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/1107297/pubmed\" target=\"_blank\" id=\"1107297\">1107297</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104956 Version 39.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45031230\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45031231\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45031235\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45031283\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45031282\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45031285\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45031286\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45031304\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45031233\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F45031306\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45031289\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45031239\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45031240\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45031224\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45031251\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45031248\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45031249\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45031258\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45031255\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45031244\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45031245\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45031246\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45031293\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45031269\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45031267\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45031270\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45031308\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45650000\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104956|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tobramycin-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Tobramycin (oral inhalation): Patient drug information \t</a></li><li><a href=\"topic.htm?path=tobramycin-oral-inhalation-pediatric-drug-information\" class=\"drug drug_pediatric\">Tobramycin (oral inhalation): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}